NCT01097460已完成1 期
MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 3
- 主要终点
- Incidence of Treatment-emergent AE's
研究概览
简要总结
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
详细描述
Phase 1: Safety and tolerability of the MM-111 + Herceptin combination will be evaluated and the recommended Phase 2 dose will be determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed advanced breast cancer that is amplified for HER2, based on archived tumor biopsy (IHC 2+ or greater)
- •Patients must have histologically or cytologically confirmed advanced breast cancer that is heregulin positive based on fresh tumor tissue biopsy
- •The patient's cancer must have recurred, progressed or not responded to standard chemotherapy or other standard treatment. Prior therapies may include but are not limited to Herceptin, Tykerb (lapatinib), anthracyclines, and taxanes
- •Patients must be ≥ 18 years of age
- •Patients or their legal representatives must be able to understand and sign an informed consent
- •Patients may have measurable (per RECIST 1.1) or non-measurable tumor(s) (for Phase 1)
- •Patients should have ECOG Performance Score (PS) 0, 1 or 2 (for Phase 1).
- •Patients should have a life expectancy of at least 12 weeks
- •Patients must have adequate bone marrow reserves
- •Patients must have adequate hepatic function
- •Patients must have adequate renal function
- •Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy.
- •Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-111.
排除标准
- •Patients who are pregnant or lactating
- •Patients with an active infection or with an unexplained fever > 38.5°C (101.3° F) during screening visits or on the first scheduled day of dosing.
- •Patients with untreated and/or symptomatic metastatic CNS malignancies.
- •Patients with known hypersensitivity to any of the components of MM-111 or who have had hypersensitivity reactions to fully human monoclonal antibodies, including Herceptin.
- •Patients who have received other recent antitumor therapy including:
- •Treatment with Herceptin within the 28 days prior to the first scheduled day of dosing with MM-111
- •Investigational therapy administered within the 28 days prior to the first scheduled day of dosing MM-111 (Dosing in less than 28 days' since receiving investigational therapy is acceptable once a time interval equal to at least five half-lives of the investigational agent has passed.)
- •Any standard chemotherapy, Tykerb (lapatinib) or radiation within 14 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of MM-111
- •Patients who have previously received MM-111
- •Patients with NYHA Class III or IV congestive heart failure or LVEF < 50%
- •Patients with a history of allogeneic transplant
- •Patients with known HIV, hepatitis B or C (if patients have previously been treated for hepatitis C and have undetectable viral loads, they can be considered eligible for the trial)
- •Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
研究组 & 干预措施
MM-111 + Herceptin
Experimental
MM-111 will be combined with Herceptin
干预措施: MM-111 + Herceptin (Drug)
结局指标
主要结局
Incidence of Treatment-emergent AE's
时间窗: 2 years
次要结局
- To Determine the Recommended Phase 2 Doses of MM-111 + Herceptin in Combination(2 years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersHer2 Amplified Solid TumorsMetastatic Breast CancerNCT00911898Merrimack Pharmaceuticals20
已完成
1 期
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerHER-2 Gene AmplificationNCT01304784Merrimack Pharmaceuticals100
已完成
1 期
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersLocally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast CancerNCT01209195Merrimack Pharmaceuticals41
进行中（未招募）
不适用
A Study of MM-111 and Paclitaxel with or without Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and StomachHER2 distal esophageal, Gastroesophageal (GE) junction or gastric carcinoma.MedDRA version: 16.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003798-25-GBMerrimack Pharmaceuticals Inc.180
进行中（未招募）
1 期
A Study of MM-111 and Paclitaxel with Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and StomachEUCTR2012-003798-25-DKMerrimack Pharmaceuticals Inc.151